In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trust Us: Is Pharma’s COVID-19 Vaccine Pledge Convincing?

Executive Summary

Missteps on convalescent plasma and the revoked authorization of hydroxychloroquine – paired with US president Trump’s cheerleading for the rapid approval of a COVID-19 vaccine – has eroded public trust in the US FDA. Can a safety and efficacy pledge from vaccine developers tamp down public skepticism?

You may also be interested in...



Coronavirus Update: US Public Confidence In COVID-19 Vaccines Declines

Confidence in the vaccine has slipped in the US, regardless of political affiliation.

Pfizer's COVID-19 Vaccine Commercialization Plan Includes DTC Campaign

The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.

Sen. Schumer Calls On HHS Head Azar To Resign

Chuck Schumer, the top Democratic senator, is calling on HHS secretary Alex Azar to resign, accusing him of putting politics over public health.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel